CHOLESTYRAMINE LIGHT (cholestyramine/aspartame)
BILE SEQUESTRANTS·HYPERCHOLESTEROLEMIA·+1
ZYDUS PHARMACEU
Indication
Hypercholesterolemia
Hypercholesterolemia is a metabolic lipid disorder characterized by abnormally elevated concentrations of circulating total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the bloodstream. Read more about Hypercholesterolemia
373 drugs 141 manufacturers
Drugs that treat it
Common Hypercholesterolemia therapies.
SLO-NIACIN (niacin)
HYPERCHOLESTEROLEMIA·+6
MAINPOINT/MAGNA
LOVASTATIN
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+7
LEGACY PHARMACE
EZETIMIBE
SELECTIVE CHOLESTEROL ABSORPTION INHIBITOR·HYPERCHOLESTEROLEMIA·+5
Major Pharamceuticals
EZETIMIBE
SELECTIVE CHOLESTEROL ABSORPTION INHIBITOR·HYPERCHOLESTEROLEMIA·+5
ASCEND LABORATO
EZETIMIBE
SELECTIVE CHOLESTEROL ABSORPTION INHIBITOR·HYPERCHOLESTEROLEMIA·+5
ZYDUS PHARMACEU
ROSUVASTATIN CALCIUM
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
TRIS PHARMA INC
ZYPITAMAG (pitavastatin magnesium)
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+2
MEDICURE INTERN
ATORVASTATIN CALCIUM
ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
NORTHSTAR RX LL
Filter & compare in the drug finder →Opens the drug finder with Hypercholesterolemia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHypercholesterolemia is a metabolic lipid disorder characterized by abnormally elevated concentrations of circulating total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the bloodstream.
Primarily impacting the cardiovascular and vascular systems across pediatric and adult populations, it can arise from primary polygenic or monogenic defects, such as low-density lipoprotein receptor mutations, or secondary causes including metabolic disease, diet, and medications.
Pathophysiologically, the sustained excess of atherogenic lipoprotein particles promotes their infiltration, oxidation, and accumulation within arterial walls, driving systemic atherosclerosis and markedly increasing the risk of coronary artery disease, myocardial infarction, and ischemic stroke.
- medlineplus.gov
Hypercholesterolemia is a metabolic lipid disorder characterized by abnormally elevated concentrations of circulating total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the bloodstream Primarily impacting the cardiovascular and vascular systems across pediatric and adult populations, it can arise from primary polygenic or monogenic defects, such as low-density lipoprotein receptor mutations, or secondary causes including metabolic disease, diet, and medications
- nih.gov
Hypercholesterolemia is a metabolic lipid disorder characterized by abnormally elevated concentrations of circulating total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the bloodstream
- nih.gov
Primarily impacting the cardiovascular and vascular systems across pediatric and adult populations, it can arise from primary polygenic or monogenic defects, such as low-density lipoprotein receptor mutations, or secondary causes including metabolic disease, diet, and medications
- physio-pedia.com
Primarily impacting the cardiovascular and vascular systems across pediatric and adult populations, it can arise from primary polygenic or monogenic defects, such as low-density lipoprotein receptor mutations, or secondary causes including metabolic disease, diet, and medications Pathophysiologically, the sustained excess of atherogenic lipoprotein particles promotes their infiltration, oxidation, and accumulation within arterial walls, driving systemic atherosclerosis and markedly increasing th...
- medlineplus.gov
Pathophysiologically, the sustained excess of atherogenic lipoprotein particles promotes their infiltration, oxidation, and accumulation within arterial walls, driving systemic atherosclerosis and markedly increasing the risk of coronary artery disease, myocardial infarction, and ischemic stroke
- nih.gov
Pathophysiologically, the sustained excess of atherogenic lipoprotein particles promotes their infiltration, oxidation, and accumulation within arterial walls, driving systemic atherosclerosis and markedly increasing the risk of coronary artery disease, myocardial infarction, and ischemic stroke
Personalize your experience
Follow Hypercholesterolemia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.